Novartis reported another late-stage failure as its Harbor Phase 3 trial of del-desiran missed a crucial primary endpoint. The setback follows a high-profile heart disease trial disappointment earlier, leaving Novartis with limited wins from a recent acquisition of the Avidity-linked asset. Del-desiran is part of Novartis’ push into pathways tied to the acquired Avidity program, and a missed endpoint reduces the likelihood of near-term regulatory progress and commercial scaling. The update is likely to affect internal portfolio resource allocation and investor expectations for the remaining pipeline tied to the Avidity deal.